RxDoctor Payments Data

Kathleen Lambert, MD

Hematology & Oncology · Conyers, GANPI 1689651390

Payments from drug & device makers

$90,106in general payments, 2019–2025

Across 172 payments — averaging $523.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$48K
  • Amgen$39K
  • Merck$695
  • Novartis$276
  • AbbVie$182
  • Daiichi Sankyo Inc.$179
  • plus $2K from 39 others

What the payments were for

  • Consulting fees$7,78515%
  • Speaking & faculty fees$39,93876%
  • Travel & lodging$8642%
  • Food & beverage$3,7947%
  • Education$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,106 in reported general payments places this provider in the 75th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$33,593
Medicare patients
130
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib40$640,397
PomalystPomalidomide21$433,447
RevlimidLenalidomide21$357,057
KisqaliRibociclib Succinate18$289,078
TagrissoOsimertinib Mesylate13$207,426
CalquenceAcalabrutinib Maleate12$169,399
TavalisseFostamatinib Disodium12$130,962
EliquisApixaban118$101,856
XareltoRivaroxaban31$33,851
Oxycodone Hcl75$4,347
Exemestane22$3,178
Anagrelide Hcl20$2,755
Imatinib Mesylate20$1,685
Gabapentin97$1,652
Tenofovir Disoproxil Fumarate11$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$25$640,39740 claims
AstraZenecaTagrisso, Calquence$177$376,82525 claims
Bristol Myers SquibbRevlimid$106$357,05721 claims
NovartisKisqali$276$289,07818 claims
Rigel Pharmaceuticals, Inc.Tavalisse$20$130,96212 claims
PfizerEliquis$74$101,856118 claims
Johnson & JohnsonXarelto$48,023$33,85131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Conyers

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →